The authors have previously reported a homogeneous time-resolved fluorescence proximity immunoassay for estradiol. The assay was based on luminescence resonance energy transfer between a long lifetime fluorescent europium(III) chelate-dyed nanoparticle donor and a short lifetime, near-infrared fluorescent acceptor. The energy transfer prolonged the lifetime of the sensitized acceptor emission, and the fluorescence of the acceptor was measured using a time-resolved detection. The developed immunoassay was employed to screen inhibitors for enzyme 17β-hydroxysteroid dehydrogenase type 1. The enzyme overexpressed in MCF-7 cells catalyzed a reversible conversion of estrone to 17β-estradiol. The inhibition efficiency of the tested molecule was obtained by comparing the final concentration of converted estradiol after 60 min of conversion reaction in a sample and in a conversion control not containing an inhibitor. The Z′ factor calculated using the E2 concentrations of the homogeneous assay was 0.64, demonstrating a relatively good performance of the assay. The results from the homogeneous assay were comparable with the results obtained using radioactively labeled estrone as a substrate and high-performance liquid chromatography (HPLC) separation of estrone and converted estradiol after the enzyme reaction. Thus, this homogeneous assay can simplify the primary screening of potential new drug molecules by replacing a tedious radiometric HPLC method.
T
HERE HAS BEEN A GROWING DEMAND for efficient highthroughput screening (HTS) methods, which can be used by pharmaceutical companies in their effort of finding new potential drug compounds. In many cases, a target molecule for these drugs is a specific enzyme or a receptor, for example, kinases or Gprotein-coupled receptors.
1,2 HTS methods allow a cost-efficient testing of interactions between several thousands of potential drug compounds and the target molecule of interest. Homogeneous assays simplify HTS because no laborious separation steps are required. Homogeneous assay technologies include, for example, assays based on fluorescence resonance energy transfer (FRET), fluorescence polarization, fluorescence correlation spectroscopy, and scintillation proximity assay. 3, 4 Hydroxysteroid dehydrogenases (HSDs) are enzymes, which have a critical role in biosynthesis and inactivation of steroid hormones. Currently, 11 different types of the enzyme 17β-HSD have been identified from mammalian tissues. 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD-1) is located in the cytoplasm of cells, and it belongs to the gene family of short-chain dehydrogenases/reductases formerly known as short-chain alcohol dehydrogenases. 5 It is predominantly expressed in placenta, ovaries, and breast cancer cells, especially in tumor cells of postmenopausal women. 6, 7 17β-HSD-1 catalyzes a reversible reduction of estrone (E1) to 17β-estradiol (E2). Increased amounts of E2 and its metabolites (concentrations from 10 -8 to 10 -6 mol/L) have been shown to stimulate the proliferation of cancer cells. 8 If the reduction of E1 to E2 could be affected with a specific inhibitor, the levels of E2 and its metabolites in cancer cells should be lowered and cell division slowed down.
Potential inhibitors for 17β-HSD-1 can be screened by measuring E2 concentration after precisely controlled conversion reaction performed using a defined quantity of MCF-7 cells overexpressing the enzyme, substrate (E1), and a test compound. The extent of inhibition of the enzyme activity can be evaluated by comparing the production of E2 in the presence of inhibitor to that in conversion control. Conversion control has no inhibitor present in the conversion reaction, and a maximum amount of E2 is produced in given conditions. Determining an inhibition efficiency of a tested molecule by measurement of a final product of an enzyme reaction has been used successfully in earlier studies. Using homogeneous assays based on FRET, inhibitors have been found for the ubiquitin transfer system and for production of human interferon-γ, for example.
We describe here an application of a homogeneous competitive E2 immunoassay 11 for screening of inhibitors for 17β-HSD-1. The assay was based on luminescence resonance energy transfer and time-resolved detection. The assay used a long lifetime fluorescent europium(III) chelate-dyed nanoparticle coated with an E2-specific fragment of antibody (Fab) as a donor and a short lifetime near-infrared fluorophore conjugated to E2 as an acceptor. When the donor and the acceptor were in close proximity, the energy was transferred from the donor to the acceptor via nonradiant dipoledipole interactions 12 leading to sensitized acceptor emission with prolonged fluorescence lifetime. Thus, the emission from the acceptor can be measured using time-resolved detection. Nanoparticles had a very high specific activity because 1 nanoparticle contained thousands of embedded europium(III) chelates 13 and tens of them were in proximity of a single acceptor molecule, 11 leading to enhanced energy transfer signal compared to other homogeneous assay methods based on FRET using conventional labels.
The aim of our study was to demonstrate the feasibility of the homogeneous immunoassay for E2 in enzyme inhibitor screening. The immunoassay was optimized to be the most suitable for inhibitor screening, and several potential inhibitors were tested using cell-based enzyme conversion reaction. Efficiencies of the potential inhibitors determined using the homogeneous assay were compared with results obtained from high-performance liquid chromatography (HPLC) separation of converted radioactive E2.
MATERIALS AND METHODS
Assay buffer containing 50 mmol/L Tris-HCl, pH 7.75, 0.9% (w/v) NaCl, 0.05% (w/v) NaN 3 , 0.01% (v/v) Tween40, 0.05% (w/ v) bovine-γ-globulin, 20 µmol/L diethylenetriaminepentaacetate, and 0.5% (w/v) bovine serum albumin (BSA) was purchased from Innotrac Diagnostics (Turku, Finland) and used in dilutions of immunoassays, unless another solution is mentioned. Fluorescence emissions were measured using 1234 Fluorometer (Wallac, PerkinElmer Life and Analytical Sciences, Turku, Finland) equipped with a 730-nm band-pass emission filter with a 10-nm bandwidth (Coherent Inc., Santa Clara, CA), a red-sensitive R2949 photomultiplier tube (Hamamatsu Photonics, Shimokanzo, Japan), and a DUG11 excitation filter (Wallac, PerkinElmer Life and Analytical Sciences). All measurements were made in triplicate.
Preparation of assay components
A near-infrared fluorescent label AlexaFluor 680 carboxylic acid, succinimidyl ester (Molecular Probes, Eugene, OR), was conjugated to E2 to create the acceptor conjugate. All immunoassays were performed in Maxisorb microtitration wells from Nunc (Roskilde, Denmark) using a 96-well format. The wells were blocked with BSA to prevent nonspecific binding of particles on the well surfaces.
11
Europium(III) chelate-dyed nanoparticles (Seradyn, Indianapolis, IN) with a 107-nm diameter were covalently coated with an E2-specific fragment of antibody (Fab S16) produced in our laboratory. 11, 14 In the coating reaction, we used 3.9 × 10 12 nanoparticles and 1.67 mg of Fab S16 in a total volume of 315 µL. After the coupling of Fab S16 on the surface of the particle, the remaining activated carboxyl acid groups were saturated with 50 mmol/L ethanolamine (Sigma-Aldrich, St. Louis, MO). To dissolve Fab S16-coated nanoparticles that had precipitated during the coating reaction, the pH of the solution was raised to 8.5 and the particles were sonicated with Labsonic U microtip-sonicator (B. Braun, Germany) until no aggregates were visible. Nanoparticles were separated from unbound Fab S16 using Nanosep Omega 300 kDa centrifugal devices (Pall Corp., Ann Arbor, MI) by washing the particles 4 times with 400 µL of 2 mmol/L Tris-HCl, pH 8.5, containing 0.01% (v/v) Tween20.
Conversion of E1 using 17␤-HSD-1 overexpressed in MCF-7 cells
MCF-7 cells transfected with a stable 17β-HSD1-1 expression vector (Hormos Medical Corp., Turku, Finland) were used for the conversion of E1 to E2. Stock cultures were grown in phenol redfree Dulbecco's modified eagle medium (DMEM) containing 2 mmol/L L-glutamine and 0.25 mg/mL geniticine solution (SigmaAldrich). The medium was supplemented with 10% (v/v) fetal bovine serum, which was treated twice with dextran-coated charcoal (2×DC FBS, Autogen Bioclear UK Ltd., Wiltshire, UK).
The stock cultures of the cells were harvested by trypsinization (Trypsin-EDTA solution 10×, Sigma-Aldrich); simultaneously, the cells were diluted into appropriate concentration. Cells were seeded into a 96-well plate and allowed to attach overnight in a humidified incubator at 37°C, forming a monolayer culture. Phenol red-free DMEM supplemented with 10% (v/v) 2×DC FBS and 2 mmol/L L-glutamine was used as a plating medium. After overnight incubation, the cell medium was changed into a new plating medium also containing a potential inhibitor dissolved in 100% (v/ v) DMSO and E1 as a substrate. The substrate for the samples to be analyzed with the homogeneous assay contained nonlabeled E1 in the final concentration of 20 nmol/L. For the HPLC samples, a portion of the substrate was [ 3 H]-labeled. Conversion controls contained the same amount of DMSO and substrate as actual samples but no inhibitor to be tested. After 1-h incubation at room temperature, the conversion reactions to be analyzed with HPLC were stopped by adding trichloroacetic acid (TCA; Sigma-Aldrich), and supernatants were transferred into the HPLC-running plate. The samples to be measured with the homogeneous immunoassay were collected from the 96-well culture plates, centrifuged to remove any cells, and frozen with dry ice.
Altogether, 11 inhibitors designed and produced by Hormos Medical Corp. were tested with 2 different concentrations (1 µmol/ L and 10 µmol/L) using both the HPLC separation method and the Enzyme Inhibitor Screening Using a Homogeneous Assay homogeneous immunoassay. To determine the reproducibility of the conversion reaction and the homogeneous assay, 2 inhibitors and a conversion control were analyzed using parallel samples collected from 6 different cell culture wells.
HPLC detection of inhibition efficiency
HPLC was used to separate E1 and converted E2. 15 The ratio of [ 
Optimization of the immunoassay
Three different amounts of nanoparticles (3 × 10 7 , 5 × 10 7 , or 7.5 × 10 7 particles in 25 µL buffer) and 10 µL of standards containing 0 to 25 nmol/L or background solution containing 10 µmol/L of E2 were added to BSA-blocked wells. The wells were incubated for 30 min at room temperature with low shaking using Plate Shake (PerkinElmer Life and Analytical Sciences). Thereafter, 15 µL of 40 nmol/L E2-Alexa680 conjugate was added into each well; the wells were protected from light with aluminum foil, and incubation was continued for 15 min. Sensitized acceptor emission generated by energy transfer was measured with the 1234 Fluorometer using a 1-ms cycle time, 1000 repeats, and 2 measurement windows: 75-µs delay and 50-µs measurement or 75-µs delay and 400-µs measurement. Incubation was continued for an additional 45 min to achieve a total 60-min incubation time of E2-Alexa680 conjugate, and the measurement was repeated.
Immunoassay for cell-based conversion samples
Fab S16-coated nanoparticles (3 × 10 7 particles in 25 µL buffer) and 10 µL of standards, background solution, or cell-based conversion samples were added to BSA-blocked wells as previously stated. Standards containing 0 to 50 nmol/L and background solution containing 10 µmol/L of E2 were diluted in phenol redfree DMEM containing 20 nmol/L E1 and 10% 2×DC FBS to imitate the sample matrix. E2-Alexa680 conjugate was added to the wells and incubations, and measurements were performed as previously stated (Fig. 1) . The inhibition efficiencies were calculated by comparing the amount of E2 in an inhibitor sample and in a conversion control using equation (1) . All the inhibitor samples were measured twice in separate assays to confirm the immunoassay results.
Inhibition E conc of the sample E conc of conversioncon
The Z′ factors 16 were calculated separately for both measurement windows and E2-Alexa680 conjugate incubation times using 2 different approaches to estimate the performance of the inhibitor screening assay. The Z′ sg factors were obtained by comparing the signals and their standard deviations (SD sg ) of a positive and a negative control using equation (2) . To calculate the Z′ conc factors, the concentrations and their standard deviations (SD conc ) of a positive and a negative control were compared using equation (3) . The positive control was the 0 nmol/L E2 standard, which represented 100% inhibition of the conversion reaction. For practical reasons, we used in equation (3) centration. The negative control was the E2 standard, which represented 0% inhibition (the conversion control). By regulating the amount of the sample, the conversion control could be situated close to the EC 50 value (the E2 concentration, which gave 50% of the maximum signal of the assay and was represented by 3.75 nmol/L standard) or close to the EC 20 value (the E2 concentration, which gave 20% of the maximum signal of the assay and was represented by 25.0 nmol/L standard) of the assay. 
RESULTS AND DISCUSSION

Conversion of E1 using 17␤-HSD-1 overexpressed in MCF-7 cells
The conversion reaction was optimized by testing several different densities of MCF-7 cells overexpressing 17β-HSD-1 and reaction conditions, such as incubation time, temperature, and substrate concentration. The conditions were chosen in such a manner that the converted amount of E2 in the conversion control was approximately 4 nmol/L after the enzyme reaction, and a reversible reaction (from E2 to E1) was extremely unlikely. For the homogeneous assay, the conversion reaction was stopped by freezing, and any cells detached from the culture well were removed by centrifuging. For HPLC separation, all proteins in the samples were precipitated by the addition of TCA. For the immunoassay samples, precipitation was not applicable because the capacity of the assay buffer was not sufficient to neutralize the samples containing TCA (data not shown).
Optimization of the immunoassay
The sensitivity of the immunoassay depended heavily on the amount of the 107-nm europium(III) chelate-dyed nanoparticles in the well (Table 1 ). The sensitivity of the assay improved when a smaller amount of particles was used because the total amount of the Fab fragment decreased in the competitive assay. 17 The longer incubation time of E2-Alexa680 conjugate (60 min of incubation) increased the EC 50 value of the assay significantly because the assay was performed as a so-called back-titration assay: E2 was first incubated with the particles until a binding equilibrium was reached, before a large excess of E2-Alexa680 conjugate was added. The conjugate could bind only to those Fab S16 fragments that were not yet occupied by E2. However, when E2-Alexa680 conjugate was incubated for 60 min, it had time to replace some of the E2 bound to the Fab S16. Therefore, the maximum signal obtained from the assay was higher, but the sensitivity of the assay decreased compared to the 15-min incubation of E2-Alexa680 conjugate. Nevertheless, we chose to perform the assay as a back-titration assay because it is a more sensitive assay method than a traditional competitive assay. 18, 19 These results were similar to those obtained using 92-nm donor particles in the previous study. The immunoassay was optimized for inhibitor screening so that the E2 concentration of the conversion control (typically 4 nmol/L) was close to the EC 50 value of the assay (Fig. 2) . The EC 50 value was in the middle of the steep part of the standard curve, where E2 concentration measurement was the most precise. Therefore, the conversion controls and also the poor inhibitor samples, whose E2 concentrations were situated close to the EC 50 value of the immunoassay, generally had smaller concentration coefficients of variation (CV%s) compared to the efficient inhibitor samples, whose signals were close to the maximum signal of the assay EC 50 values (nmol/L) were calculated separately for each amount of particles in a well, incubation times of E2-Alexa680 conjugate, and measurement windows. The maximum signal-to-background ratios are represented inside parentheses.
FIG. 2.
A typical standard curve of the homogeneous immunoassay for E2. The EC 50 value (B) was 2.9 nmol/L when the assay was measured after 15 min of E2-Alexa680 conjugate incubation and using the 400-µs measurement window (n). The conversion controls and poor inhibitors (C) were located close to the EC 50 value of the assay. Samples containing a very efficient inhibitor (A) had only a minute amount of E2. Thus, the employed assay range was situated between points A and C. The EC 20 value of the assay is marked with D. The concentration CV% profile is represented by p.
where the concentration measurements had weaker precision.
With the 107-nm donor particles, the EC 50 value was close to 4 nmol/L when 3 × 10 7 or 5 × 10 7 particles/well was used in the assay (Table 1) . To gain a sensitive assay with an improved dynamic range for the inhibitor-screening purpose, 3 × 10 7 particles/well was used in the screening assay, although the signal level of the assay was quite low, possibly increasing the CV% of the measurements.
Immunoassay for cell-based conversion samples
Performance of the immunoassay. When the conversion control was situated close to the EC 20 value of the assay, the Z′ sg factors, which were calculated using the signals and their standard deviations (equation (2)), improved significantly ( Table 2) . The assay had a wider employed dynamic range, and the standard deviations of the measured signals remained approximately the same compared to the situation in which the conversion control was close to the EC 50 value of the assay.
When the Z′ factors were calculated from the concentrations and their standard deviations (equation (3)), the performance of the assay improved if the conversion control was situated close to the EC 50 value of the immunoassay, especially with the shorter measurement window. In that case, the screening assay had a narrower dynamic range, but the conversion control (together with the poor inhibitor samples) had considerably smaller variation in concentration measurements, leading to the better detection of poor inhibitor samples compared to the situation in which the conversion control was close to the EC 20 value of the assay. Because the screening assay was based on the comparison of the E2 concentrations and not the signals of conversion controls and inhibitor samples, the Z′ conc factors were more essential than the Z′ sg factors.
The incubation time of the E2-Alexa680 conjugate did not significantly alter the Z′ conc factor, but the measurement window was a noteworthy factor. The variation in concentration measurements was smaller with the 400-µs measurement window because the obtained signal levels of the assay were higher, which led to more reproducible signal measurements and better Z′ conc factors compared to the 50-µs measurement window. Thus, after 15 min of E2-Alexa680 conjugate incubation and using the 400-µs measurement window, the performance of the immunoassay was optimal for the inhibitor screening purpose. With a more modern measurement device, preferably equipped with a laser excitation, the obtained signals should increase significantly leading to better Z′ factors, especially with the 50-µs measurement window. Thus, the assay performance can still be further improved.
Inhibition efficiencies of the samples
Altogether, 11 different inhibitor samples (a-k) with diverse inhibition efficiencies were tested (Fig. 3) . All the samples were measured twice in separate immunoassays to confirm the immunoassay results. Two concentrations (10 µmol/L and 1 µmol/L, marked with 1 and 2, respectively) of all the inhibitors were used in conversion reactions. The inhibition efficiencies obtained from the homogeneous assay were compared to the results from HPLC separation of radioactively labeled E1 and converted E2. The average result of the 2 separate immunoassays was very close to the results from HPLC separation. The largest difference was detected with the samples containing very poor inhibitors. Although E2 concentrations of the poor inhibitors and the conversion controls were detected with the best precision, the deviation of the concentrations between these samples still had a higher absolute value compared to the good inhibitors. The lowest inhibition efficiency that the homogeneous assay was able to distinguish reliably from the conversion control was estimated by calculating 2 times the standard deviation of 6 separate conversion controls measured with 3 assay replicates. With the optimized immunoassay, the result of this calculation equaled approximately 30% inhibition efficiency. Thus, if the inhibition efficiency of a sample was more than 30%, the E2 concentration of the sample differed significantly from the E2 concentration of the conversion control with 95.5% probability. When samples were analyzed using the HPLC separation method, 13 inhibitor samples of the total 22 samples had a higher inhibition efficiency than 30%. Using the homogeneous assay, 12 samples had a higher inhibition efficiency than 30%. Thus, there was only 1 inhibitor sample (i1) that was not distinguished from the conversion control using the immunoassay compared to HPLC method.
The average immunoassay result of sample i1, calculated from 2 separate measurements, differed significantly from the result obtained from the HPLC separation method (15% and 43%, respectively). Also, the variation between the results of the 2 separate immunoassays was very small because the inhibition efficiencies were 13% and 17%. This indicated fluctuation in E2 concentrations in parallel samples caused by the cell-based conversion reaction because the samples for the immunoassay and for the HPLC were collected from separate cell culture wells. Thus, the homogeneous assay could be used to reliably screen inhibitors that had more than 30% inhibition efficiency, if more than 1 parallel sample was measured. If the inhibition efficiency was lower than 30%, the probability that the sample actually differed from conversion control was smaller. On the other hand, the aim of the primary screening was to detect potent new drug molecules, whereas weaker inhibitors were not as interesting.
Variation of E2 concentrations in parallel samples
The variance of E2 concentrations in 3 sample types (an efficient inhibitor, a poor inhibitor, and a conversion control) was determined by collecting samples from 6 different cell culture wells of each sample type. Each collected sample was measured using 3 replicates in the developed assay (Table 3) . Most of the samples had concentration CV%s in the assay below 5% (concCV% within the culture well). Thus, the immunoassay performance of the samples had been acceptable. However, there were some individual culture wells whose E2 concentration differed statistically significantly from the overall E2 average calculated from all 6 culture wells (p < 0.01 using 1 population t-test). These divergent culture wells were assayed with relatively small concCV% within the culture well. Therefore, it can be concluded that the parallel cell culture wells did have different amounts of converted E2 caused by the variation in the conversion reaction.
The rate of conversion reaction depended heavily on the amount of the enzyme in the cell culture well. Despite carefully controlled conditions of cell-based conversion reaction, there evidently was some fluctuation in the expression level of the enzyme or variation in the amount of the cells in the culture wells. The fluctuation of E2 concentrations of the conversion controls diminished the ability of the homogeneous assay to reliably detect very small inhibition efficiencies. Using a purified recombinant 17β-HSD-1 in the conversion reaction, the amount of the enzyme in the conver -FIG. 3 . The comparison of the homogeneous assay and the highperformance liquid chromatography (HPLC) method. Eleven inhibitors (a-k) tested with 2 concentrations (10 µmol/L and 1 µmol/L) were analyzed twice using 2 separate homogeneous assays (average result of 2 measurements are represented with white bars with standard deviations) and once with the radiometric HPLC separation method (black bars). Immunoassay could reliably detect samples with more than 30% inhibition efficiency, which is indicated as a dashed line. Samples containing a poor inhibitor, an efficient inhibitor, and no inhibitor (conversion control) were produced using 6 parallel cell culture wells for each sample type. Culture wells were compared to determine the variance in E2 concentrations caused by the cellbased conversion reaction. The results are obtained after 15 min of incubation of the E2-Alexa680 conjugate and using a 400-µs measurement window. a. Each culture well was measured with 3 assay replicates (n = 3). b. The culture wells whose average E2 concentration differed statistically very significantly (p < 0.01) from the overall average E2 concentration of all 6 culture wells. c. Overall average E2 concentration was calculated from all the culture well measurements (n = 18).
sion reaction could be more easily controlled and the differences between conversion reactions should be smaller. Therefore, the conversion reaction-based differences between the samples should be smaller, leading to better differentiation of very poor inhibitors from the conversion controls.
CONCLUSION
HPLC separation can be used to find inhibitors for an enzyme converting E1 to E2. However, the HPLC separation method requires radioactively labeled components, and more important, it is very time-consuming and tedious; thus, it is not a very suitable method for HTS. We have described here a simple and easily automated homogeneous immunoassay that could replace the HPLC separation method in primary screening of conversion enzyme inhibitors.
The homogeneous immunoassay for E2 could accurately and reproducibly detect the concentration of E2 after the cell-based conversion reaction, and the inhibitor efficiency of the tested molecule could be deduced. Fab S16 used in the immunoassay was very specific for E2, and it had cross-reactivity with E1 less than 0.1%. 14 However, there is a slight possibility that a tested inhibitor molecule could bind to a Fab fragment, which would be interpreted as a weak inhibition efficiency of the tested molecule. By adding control samples into the immunoassay containing only the tested molecules, possible cross-reactivity would be detected. Therefore, the homogeneous assay could distinguish high probability inhibitors, which have an inhibition efficiency more than 30%, from conversion controls. Even smaller inhibition efficiencies could be detected reliably with further improvements, for example, by modernizing the measurement instrument and using purified recombinant 17β-HSD-1 in the conversion reaction.
